02.04.14
A new study on Aker BioMarine Antarctic AS’s product Superba Krill oil will be featured in the February 2014 edition of Nutrition Research. The study investigated the effects of Superba Krill on blood lipids in subjects with “borderline high” or “high” triglyceride (TG) levels.
A total of 300 volunteers were divided into five groups and supplemented with krill oil at either 0.5, 1, 2 or 4 grams per day or placebo (olive oil). The subjects included in the study had blood TG values between 150 and 499 mg/dL. Blood lipids were measured at baseline, 6 weeks and 12 weeks of treatment.
Relative to subjects in the placebo group, those administered krill oil had a statistically significant 10.2% reduction in serum TG levels. Moreover, LDL-C levels were not increased in the krill oil groups relative to the placebo group, an important finding considering an increase in LDL-C has been observed in some fish oil trials.
"It is remarkable that krill oil, providing on average less than 400 mg per day of EPA and DHA, produced a significant 10% reduction in serum triglyceride levels," said Dr. William Harris, PhD, Professor of Medicine, University of South Dakota School of Medicine, and co-inventor of the HS Omega-3 Index Blood Test, and member of the Aker BioMarine Antarctic Science Board.
The outcome of this pooled analysis suggests that krill oil is effective in reducing a cardiovascular risk factor. However, owing to the individual fluctuations of TG concentrations measured, a study with more individual measurements per treatment group is needed to increase the confidence of these findings.
For more information: www.akerbiomarine.com
A total of 300 volunteers were divided into five groups and supplemented with krill oil at either 0.5, 1, 2 or 4 grams per day or placebo (olive oil). The subjects included in the study had blood TG values between 150 and 499 mg/dL. Blood lipids were measured at baseline, 6 weeks and 12 weeks of treatment.
Relative to subjects in the placebo group, those administered krill oil had a statistically significant 10.2% reduction in serum TG levels. Moreover, LDL-C levels were not increased in the krill oil groups relative to the placebo group, an important finding considering an increase in LDL-C has been observed in some fish oil trials.
"It is remarkable that krill oil, providing on average less than 400 mg per day of EPA and DHA, produced a significant 10% reduction in serum triglyceride levels," said Dr. William Harris, PhD, Professor of Medicine, University of South Dakota School of Medicine, and co-inventor of the HS Omega-3 Index Blood Test, and member of the Aker BioMarine Antarctic Science Board.
The outcome of this pooled analysis suggests that krill oil is effective in reducing a cardiovascular risk factor. However, owing to the individual fluctuations of TG concentrations measured, a study with more individual measurements per treatment group is needed to increase the confidence of these findings.
For more information: www.akerbiomarine.com
